Search Results - "Hepatitis B virus genetics"

Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC by Li, Shengnan, Xia, Han, Wang, Zeyu, Zhang, Xiehua, Song, Tianqiang, Li, Jia, Xu, Liang, Zhang, Ningning, Fan, Shu, Li, Qian, Zhang, Qiaoling, Ye, Yingnan, Lv, Jiayu, Yue, Xiaofen, Lv, Hongcheng, Yu, Jinpu, Lu, Wei

“…Background and Aims: The intratumoral microbiome has been reported to regulate the development and progression of cancers. We aimed to characterize…”
Get full text

Overview of hepatitis B viral replication and genetic variability by Tong, Shuping, Revill, Peter

“…Chronic infection with hepatitis B virus (HBV) greatly increases the risk for liver cirrhosis and hepatocellular carcinoma (HCC). HBV isolates worldwide can be…”
Get full text

Immunobiology and pathogenesis of hepatitis B virus infection by Iannacone, Matteo, Guidotti, Luca G

“…Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a persistent infection, ultimately leading to cirrhosis and…”
Get full text

Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis by Huang, Daniel Q., Tamaki, Nobuharu, Lee, Hyung Woong, Park, Soo Young, Lee, Yu Rim, Lee, Hye Won, Lim, Seng Gee, Lim, Tae Seop, Kurosaki, Masayuki, Marusawa, Hiroyuki, Mashiba, Toshie, Kondo, Masahiko, Uchida, Yasushi, Kobashi, Haruhiko, Furuta, Koichiro, Izumi, Namiki, Kim, Beom Kyung, Sinn, Dong Hyun

“…Background: Comparative outcomes of HBV-infected compensated cirrhosis with low-level viremia (LLV) versus maintained virological response (MVR) are unclear…”
Get full text

Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma by D'souza, Simmone, Lau, Keith Ck, Coffin, Carla S, Patel, Trushar R

“…Chronic infection with viral hepatitis affects half a billion individuals worldwide and can lead to cirrhosis, cancer, and liver failure. Liver cancer is the…”
Get more information

Mechanisms of HBV-induced hepatocellular carcinoma by Levrero, Massimo, Zucman-Rossi, Jessica

“…Hepatitis B virus (HBV) contributes to hepatocellular carcinoma (HCC) development through direct and indirect mechanisms. HBV DNA integration into the host…”
Get full text

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D by Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia Rossana, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Manuilov, Dmitry, Suri, Vithika, An, Qi, Da, Ben, Flaherty, John, Osinusi, Anu, Liu, Yang, Merle, Uta, Schulze zur Wiesch, Julian, Zeuzem, Stefan, Ciesek, Sandra, Cornberg, Markus, Lampertico, Pietro

“…In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine…”
Get full text

HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression by Wang, Yufei, Zhao, Man, Zhao, Lina, Geng, Yu, Li, Guanghao, Chen, Lin, Yu, Jingxuan, Yuan, Hongfeng, Zhang, Huihui, Yun, Haolin, Yuan, Ying, Wang, Guowen, Feng, Jinyan, Xu, Liang, Wang, Shuai, Hou, Chunyu, Yang, Guang, Zhang, Ningning, Lu, Wei, Zhang, Xiaodong

“…Hepatitis B virus (HBV) infection is a major driver of hepatocarcinogenesis. Ferroptosis is a type of iron-mediated cell death that can suppress liver…”
Get more information

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection by Lampertico, Pietro, Agarwal, Kosh, Berg, Thomas, Buti, Maria, Janssen, Harry L.A., Papatheodoridis, George, Zoulim, Fabien, Tacke, Frank

“…Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and…”
Get full text

Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories by Razavi-Shearer, D., Child, H., Voeller, A., Buti, M., Tacke, F., Terrault, N., Zeuzem, S., Abbas, Z., Akarca, U.S., Al Masri, N., Alalwan, A., Blomé, M. Alanko, Jerkeman, A., Aleman, S., Kamal, H., Alghamdi, A., Al-Hamoudi, W., Aljumah, A., Altraif, I., Amarsanaa, J., Asselah, T., Babameto, A., Berg, T., Biondi, M., Braga, W., Brandão-Mello, C., Brunetto, M., Cardoso, M., Martins, A., Chen, C.-J., Yang, H.-I., Chen, P.-J., Chuang, W.-L., Garza, L. Cisneros, Coco, B., Coffin, C., Coppola, N., Cornberg, M., Craxi, A., Crespo, J., Cuko, L., De Ledinghen, V., Etzion, O., Ferreira, P., Forns, X., Foster, G., Fung, J., Gaeta, G., García-Samaniego, J., Genov, J., Gheorghe, L., Gholam, P., Gish, R., Glenn, J., Hamid, S., Hercun, J., Hsu, Y.-C., Hu, C.-C., Huang, J.-F., Idilman, R., Jafri, W., Jelev, D., Jia, J., Kao, J.-H., Khan, A., Kim, D.Y., Lagging, M., Lampertico, P., Lázaro, P., Lazarus, J.V., Lobato, C., Marotta, P., Mendes-Correa, M.C., Méndez-Sánchez, N., Navas, M.-C., Orrego, M., Piracha, Z., Qureshi, H., Ramji, A., Rodríguez, M., Rosenberg, W., Roulot, D., Saeed, U., Safadi, R., Sanai, F., Sanchez-Avila, J.F., Sarrazin, C., Seto, W.-K., Simonova, M., Tanaka, J., Tsendsuren, O., Valente, C., Villalobos-Salcedo, J.M., Wong, G., Wong, V., Yip, T., Wu, J.-C., Yu, M.-L., Yurdaydin, C., Zuckerman, E.

“…Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV…”
Get full text

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference by Cornberg, Markus, Lok, Anna Suk-Fong, Terrault, Norah A., Zoulim, Fabien, Berg, Thomas, Brunetto, Maurizia R., Buchholz, Stephanie, Buti, Maria, Chan, Henry L.Y., Chang, Kyong-Mi, Dandri, Maura, Dusheiko, Geoffrey, Feld, Jordan J., Ferrari, Carlo, Ghany, Marc, Janssen, Harry L.A., Kennedy, Patrick, Lampertico, Pietro, Liang, Jake, Locarnini, Stephen, Maini, Mala K., Mishra, Poonam, Papatheodoridis, George, Petersen, Jörg, Schlottmann, Silke, Wang, Su, Wedemeyer, Heiner

“…Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on…”
Get full text

Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients by Genshaft, Alex S., Subudhi, Sonu, Keo, Arlin, Sanchez Vasquez, Juan Diego, Conceição-Neto, Nádia, Mahamed, Deeqa, Boeijen, Lauke L., Alatrakchi, Nadia, Oetheimer, Chris, Vilme, Mike, Drake, Riley, Fleming, Ira, Tran, Nancy, Tzouanas, Constantine, Joseph-Chazan, Jasmin, Arreola Villanueva, Martin, van de Werken, Harmen J. G., van Oord, Gertine W., Groothuismink, Zwier M. A., Beudeker, Boris J., Osmani, Zgjim, Nkongolo, Shirin, Mehrotra, Aman, Spittaels, Kurt, Feld, Jordan, Chung, Raymond T., de Knegt, Robert J., Janssen, Harry L. A., Aerssens, Jeroen, Bollekens, Jacques, Hacohen, Nir, Lauer, Georg M., Boonstra, Andre, Shalek, Alex K., Gehring, Adam J.

“…Background and Aims: HBV infection is restricted to the liver, where it drives exhaustion of virus-specific T and B cells and pathogenesis through…”
Get full text

Attacking hepatitis B virus cccDNA – The holy grail to hepatitis B cure by Lucifora, Julie, Protzer, Ulrike

“…HBV deposits a covalently closed circular DNA form, called cccDNA, in the nucleus of infected cells. As the central transcription template, the cccDNA…”
Get full text

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant by Mason, William S, Gill, Upkar S, Litwin, Samuel, Zhou, Yan, Peri, Suraj, Pop, Oltin, Hong, Michelle L W, Naik, Sandhia, Quaglia, Alberto, Bertoletti, Antonio, Kennedy, Patrick T F

“…Chronic infection with hepatitis B virus (HBV) progresses through different phases. The first, called the immune-tolerant phase, has been associated with a…”
Get more information

Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections by Martinez, Maria Guadalupe, Boyd, Anders, Combe, Emmanuel, Testoni, Barbara, Zoulim, Fabien

“…Current antiviral therapies, such as pegylated interferon-α and nucleos(t)ide analogues, effectively improve the quality of life of patients with chronic…”
Get full text

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection by Yuen, Man-Fung, Lim, Seng-Gee, Plesniak, Robert, Tsuji, Keiji, Janssen, Harry L.A., Pojoga, Cristina, Gadano, Adrian, Popescu, Corneliu P., Stepanova, Tatyana, Asselah, Tarik, Diaconescu, Gheorghe, Yim, Hyung Joon, Heo, Jeong, Janczewska, Ewa, Wong, Alexander, Idriz, Nevin, Imamura, Michio, Rizzardini, Giuliano, Takaguchi, Koichi, Andreone, Pietro, Arbune, Manuela, Hou, Jinlin, Park, Sung Jae, Vata, Andrei, Cremer, Jennifer, Elston, Robert, Lukić, Tamara, Quinn, Geoff, Maynard, Lauren, Kendrick, Stuart, Plein, Helene, Campbell, Fiona, Paff, Melanie, Theodore, Dickens

“…In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface…”
Get full text

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels by Sonneveld, Milan J., Chiu, Shao-Ming, Park, Jun Yong, Brakenhoff, Sylvia M., Kaewdech, Apichat, Seto, Wai-Kay, Tanaka, Yasuhito, Carey, Ivana, Papatheodoridi, Margarita, van Bömmel, Florian, Berg, Thomas, Zoulim, Fabien, Ahn, Sang Hoon, Dalekos, George N., Erler, Nicole S., Höner zu Siederdissen, Christoph, Wedemeyer, Heiner, Cornberg, Markus, Yuen, Man-Fung, Agarwal, Kosh, Boonstra, Andre, Buti, Maria, Piratvisuth, Teerha, Papatheodoridis, George, Chen, Chien-Hung, Maasoumy, Benjamin

“…Nucleo(s)tide analogue (NUC) withdrawal may result in HBsAg clearance in a subset of patients. However, predictors of HBsAg loss after NUC withdrawal remain…”
Get full text

Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE) by Sonneveld, Milan J, Park, Jun Yong, Kaewdech, Apichat, Seto, Wai-Kay, Tanaka, Yasuhito, Carey, Ivana, Papatheodoridi, Margarita, van Bömmel, Florian, Berg, Thomas, Zoulim, Fabien, Ahn, Sang Hoon, Dalekos, George N, Erler, Nicole S, Höner Zu Siederdissen, Christoph, Wedemeyer, Heiner, Cornberg, Markus, Yuen, Man-Fung, Agarwal, Kosh, Boonstra, Andre, Buti, Maria, Piratvisuth, Teerha, Papatheodoridis, George, Maasoumy, Benjamin

“…Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of…”
Get more information

The landscape of viral associations in human cancers by Zapatka, Marc, Borozan, Ivan, Brewer, Daniel S., Iskar, Murat, Grundhoff, Adam, Alawi, Malik, Desai, Nikita, Sültmann, Holger, Moch, Holger, Cooper, Colin S., Eils, Roland, Ferretti, Vincent, Lichter, Peter

“…Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, for which whole-genome and—for a subset—whole-transcriptome sequencing data from…”
Get full text

Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase by Huang, Daniel Q., Tran, Andrew, Yeh, Ming-Lun, Yasuda, Satoshi, Tsai, Pei-Chien, Huang, Chung-Feng, Dai, Chia Yen, Ogawa, Eiichi, Ishigami, Masatoshi, Ito, Takanori, Kozuka, Ritsuzo, Enomoto, Masaru, Suzuki, Takanori, Yoshimaru, Yoko, Preda, Carmen M., Marin, Raluca I., Sandra, Irina, Tran, Sally, Quek, Sabrina X.Z., Khine, Htet Htet Toe Wai, Itokawa, Norio, Atsukawa, Masanori, Uojima, Haruki, Watanabe, Tsunamasa, Takahashi, Hirokazu, Inoue, Kaori, Maeda, Mayumi, Hoang, Joseph K., Trinh, Lindsey, Barnett, Scott, Cheung, Ramsey, Lim, Seng Gee, Trinh, Huy N., Chuang, Wan-Long, Tanaka, Yasuhito, Toyoda, Hidenori, Yu, Ming-Lung, Nguyen, Mindie H.

“…Background and Aims: HCC risk in chronic hepatitis B (CHB) is higher in the indeterminate phase compared with the inactive phase. However, it is unclear if…”
Get full text